Mark A Lemmon

Mark Lemmon, PhD was appointed the Co-Director of the Cancer Biology Institute and the David A. Sackler Professor of Pharmacology in 2015. Dr. Lemmon returns to Yale, where he completed his PhD in 1993, from the University of Pennsylvania’s Perelman School of Medicine. At UPenn, he was the George W. Raiziss Professor of Biochemistry and Biophysics as well as Chair of the department and an Investigator at the Abramson Family Cancer Research Institute. Dr. Lemmon’s research focuses on the signaling pathways of receptor tyrosine kinases (RTKs), which, when mutated cause cancers and other diseases.